Results 1 to 10 of about 155,441 (160)

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +2 more sources

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. [PDF]

PLoS ONE, 2016
Data on characteristics, outcomes, and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who develop pneumonitis during systemic anti-cancer therapy (pneumonitis) are currently lacking.We conducted a retrospective cohort study of 910 ...
Daichi Fujimoto, Ryoji Kato, Takeshi Morimoto, Ryoko Shimizu, Yuki Sato, Mariko Kogo, Jiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Keisuke Tomii   +11 more
doaj   +1 more source

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer

Thoracic Cancer, 2021
Background Concurrent epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) with radiotherapy in patients with EGFR‐mutant unresectable stage III non‐small cell lung cancer (NSCLC) might improve survival. However, both treatments carry a
Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang   +16 more
doaj   +1 more source

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

JTO Clinical and Research Reports, 2023
Introduction: Thoracic radiotherapy (TRT) is increasingly used in patients receiving osimertinib for advanced NSCLC, and the risk of pneumonitis is not established.
Leou Ismael Banla, MD, PhD, Alice Tzeng, MD, PhD, John P. Baillieul, Melin J. Kandekhar, MD, PhD, Kelly J. Fitzgerald, MD, PhD, Jaclyn LoPiccolo, MD, PhD, Holly A. Poitras, Daniel E. Soto, MD, Julia K. Rotow, MD, Lisa Singer, MD, PhD, Henning Willers, MD, David E. Kozono, MD, PhD, Pasi A. Janne, MD, PhD, Raymond H. Mak, MD, Zofia Piotrowska, MD, Florence K. Keane, MD, Benjamin H. Kann, MD   +16 more
doaj   +1 more source

THE INCIDENCE OF RADIATION PNEUMONITIS IN BREAST CANCER PATIENTS WHO RECEIVED RADIOTHERAPY USING 3-DIMENSIONAL TECHNIQUES

Jurnal Kedokteran Diponegoro, 2022
Background: According to the 2018 Global Cancer Observatory from the World Health Organization (WHO), breast cancer is the most common cancer in Indonesia.
Salsabila Lutfiarahma, Yan Wisnu Prajoko, Farah Hendara Ningrum, Christina Hari Nawangsih Prihharsanti   +3 more
doaj   +1 more source

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer

Scientific Reports, 2023
Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with ...
Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto   +25 more
doaj   +1 more source

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab

Advances in Radiation Oncology, 2023
Purpose: In patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), the standard of care is concurrent chemoradiation (CRT) followed by consolidative immunotherapy with durvalumab.
Brett H. Diamond, MD, Neel Belani, MD, Rebecca Masel, MD, Kathryn DeCarli, MD, MBE, Thomas DiPetrillo, MD, Jaroslaw T. Hepel, MD, Christopher G. Azzoli, MD, Humera Khurshid, MD, Abbas Abbas, MD, Paul P. Koffer, MD   +9 more
doaj   +1 more source

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Journal for ImmunoTherapy of Cancer, 2021
Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and
Lei Zheng, Julie R Brahmer, Patrick M Forde, Jarushka Naidoo, Cheng Ting Lin, Peter B Illei, Sonye K Danoff, Karthik Suresh, Christine Hann, Aanika Balaji, Melinda Hsu, Josephine Feliciano, Kristen Marrone, Valerie Lee   +13 more
doaj   +1 more source

Serial KL-6 Changes in PD-1/PD-L1 Inhibitor-Related Pneumonitis in Non-small Cell Lung Cancer: A Single-Center Prospective Pilot Study [PDF]

Tuberculosis and Respiratory Diseases
Background Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors are effective treatments for non-small cell lung cancer (NSCLC), but their use can lead to severe pneumonitis.
Jae Kyeom Sim, Juwhan Choi, Sung Won Chang, Sang Hyuk Kim, Jee Youn Oh, Kyung Hoon Min, Gyu Young Hur, Hwan Seok Yong, Jae Jeong Shim, Sung Yong Lee   +9 more
doaj   +1 more source

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series

Journal of Medical Case Reports, 2021
Background Immunotherapy has become an efficacious option in the management of solid organ malignancies. Immune-related adverse events including pneumonitis are well described and may be particularly of concern in patients receiving immunotherapy for non-
Sarah Picard, Desiree Goh, Ashley Tan, Nisha Sikotra, Eli Gabbay, Tim Clay   +5 more
doaj   +1 more source